GlassScriptPhysician profile
Caitlin Adamowicz
NPI 1104583152
$5,944.98
in general payments reported to CMS, 2019-2025
33 companies · $295 in 2025
The $295 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,847 · 2023: $2,453 · 2024: $350 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,098.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,097.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $1,219.68 | 2022-2025 | Korlym |
| Novo Nordisk INC | $882.51 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $711.18 | 2022-2023 | Jardiance, Mounjaro, Baqsimi |
| Medtronic, INC. | $550.62 | 2022-2023 | Intellis Adaptivestim, Minimed 770g |
| Sanofi-Aventis U.S. LLC | $408.52 | 2022-2023 | |
| Amgen INC. | $372.43 | 2022-2023 | Evenity, Prolia |
| Abbott Laboratories | $189.68 | 2022-2023 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $147.92 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $140.33 | 2022-2023 | Synthroid |
| Beta Bionics, INC. | $128.85 | 2024 | Ilet Bionic Pancreas |
| Xeris Pharmaceuticals, INC. | $127.46 | 2022-2023 | Recorlev, Gvoke Hypopen |
| Radius Health, INC. | $127.27 | 2022-2023 | Tymlos |
| Mannkind Corporation | $115.21 | 2022-2023 | Afrezza |
| Insulet Corporation | $103.91 | 2022-2023 | Omnipod |
| Dexcom, INC. | $83.01 | 2022-2023 | Dexcom G6 Transmitter |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $61.48 | 2023 | Unithroid |
| Ultragenyx Pharmaceutical INC. | $60.85 | 2023 | |
| Intuity Medical INC | $54.59 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Ascensia Diabetes Care US INC. | $46.44 | 2022-2023 | |
| Antares Pharma, INC. | $45.30 | 2022 | |
| Recordati_rare_diseases_inc. | $44.99 | 2023 | Isturisa, Signifor Lar |
| Alexion Pharmaceuticals, INC. | $44.51 | 2022 | |
| Currax Pharmaceuticals LLC | $40.62 | 2022-2023 | Contrave |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.95 | 2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $28.28 | 2022-2023 | |
| Ascendis Pharma Endocrinology INC | $27.31 | 2023 | |
| Amryt Pharma Holdings LTD | $23.89 | 2023 | Mycapssa |
| Renalytix Ai, INC. | $22.14 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Rhythm Pharmaceuticals, INC. | $21.32 | 2023 | Imcivree |
| Novartis Pharmaceuticals Corporation | $20.59 | 2022 | |
| Horizon Therapeutics Plc | $20.40 | 2023 | Tepezza |
| Globus Medical, INC. | $18.87 | 2025 | Senza |
| Cequr Corporation | $16.87 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Adamowicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.